What are pulmonary granulomas?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: May 29, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

From the Guidelines

Lung granulomas are small, abnormal masses of inflamed tissue that form in the lungs as part of the body's immune response to foreign substances or infections, and their management depends on the underlying cause, with a focus on identifying and treating the specific condition, as emphasized in the most recent guideline by the American Thoracic Society 1.

Causes and Characteristics of Lung Granulomas

Lung granulomas can be caused by various factors, including infections such as tuberculosis, histoplasmosis, and other fungal infections, as well as non-infectious conditions like sarcoidosis, berylliosis, and hypersensitivity pneumonitis. These granulomas typically appear as small, round shadows on chest X-rays or CT scans, ranging from a few millimeters to several centimeters in size. They form when immune cells called macrophages surround the foreign substance and then recruit other immune cells like lymphocytes and fibroblasts, creating a characteristic layered structure.

Diagnosis and Management

The diagnosis of lung granulomas involves identifying the underlying cause, which can be achieved through a combination of clinical evaluation, imaging studies, and histopathological examination. According to the American Thoracic Society guideline 1, the management of lung granulomas depends on the specific cause, with infectious granulomas requiring appropriate antimicrobial therapy, while inflammatory conditions like sarcoidosis might need corticosteroids or immunosuppressants if symptoms are significant.

Histopathological Features

The histopathological features of lung granulomas can vary depending on the underlying cause. For example, the granulomas of hypersensitivity pneumonitis are usually small and poorly formed, consisting of loose clusters of epithelioid cells and multinucleated histiocytes, often in a peribronchiolar distribution, as described in a recent study 1. In contrast, the granulomas of sarcoidosis are typically well-formed and composed of macrophage aggregates with multinucleated giant cells, as shown in Figure 1 of the American Thoracic Society guideline 1.

Key Considerations

In clinical practice, it is essential to identify the underlying cause of lung granulomas, as some conditions may require specific treatment. The most critical step in managing lung granulomas is to determine the underlying cause and develop a treatment plan accordingly, as emphasized in the recent guideline by the American Thoracic Society 1. This approach ensures that patients receive appropriate treatment and improves their morbidity, mortality, and quality of life outcomes.

Some key points to consider when evaluating lung granulomas include:

  • The size and appearance of the granulomas on imaging studies
  • The presence of symptoms such as cough, fever, or shortness of breath
  • The results of histopathological examination and laboratory tests
  • The patient's medical history and exposure to potential causes of lung granulomas

By considering these factors and following the guidelines outlined by the American Thoracic Society 1, clinicians can provide effective management and improve outcomes for patients with lung granulomas.

From the Research

Definition of Lung Granulomas

  • Lung granulomas are defined as focal aggregations of activated macrophages, Langerhans cells, and lymphocytes that form in response to persistent particulate stimuli, which can be infectious or non-infectious 2.
  • They are characterized by the recruitment and organization of activated macrophages and lymphocytes in discrete lesions, which represent an important defense mechanism against infectious organisms and non-infectious agents 3.

Formation of Granulomas

  • Granulomas form when the immune system barricades substances it perceives as foreign but is unable to remove 4.
  • The formation of granulomas involves a series of macrophage activations and transformations that recruit additional cells and produce structural changes 2.
  • Granulomas can be necrotizing or non-necrotizing, and their distribution, quality, and associated features can help narrow down the differential diagnosis for granulomatous lung disease 5.

Causes of Granulomatous Lung Disease

  • Granulomatous lung disease can be caused by infectious agents, such as mycobacteria and fungi, as well as non-infectious agents, such as hypersensitivity pneumonitis, sarcoidosis, and vasculitis 5, 4.
  • Granulomatous inflammation of the lung can also be caused by unknown reasons, leading to a systemic illness termed sarcoidosis 3.

Clinical and Radiologic Features

  • Granulomatous lung diseases comprise multiple entities with variable clinical manifestations and outcomes 4.
  • The imaging findings of granulomatous lung diseases are rarely specific and can mimic malignancies, often triggering an extensive diagnostic workup 4.
  • Radiologists must be familiar with the clinical manifestations and imaging findings of these entities to generate appropriate differential diagnoses 4.

References

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Research

The Formation and Function of Granulomas.

Annual review of immunology, 2018

Research

Pulmonary granulomatous inflammation: From sarcoidosis to tuberculosis.

Seminars in respiratory infections, 2003

Research

Noninfectious Granulomatous Diseases of the Chest.

Radiographics : a review publication of the Radiological Society of North America, Inc, 2020

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.